🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Anuh Pharma Limited ANUHPHR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.anuhpharma.com
Company Profile ↓
₹79.87
-6.08% 1Y
Mkt Cap₹800.49 Cr
P/E18.15
P/B2.33
Div. Yield1.83%
52W High₹96.74
52W Low₹65.75
Book Value₹35.14
EPS (TTM)₹4.40

Company Overview

Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti biotic, anti platelet, anti-histamines, and intermediates; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic. The company also develops products, such as anticoagulant, antagonist, anti convulsants, anty-ulcerative, anty-ulcerative, anticholinergics, anti-anemic, antidepressant, and mucolytic agents. It also exports its products. Anuh Pharma Limited was incorporated in 1960 and is headquartered in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.4%.

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 18.1, below the sector median of 36.4.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.02.

Recent Developments

  • Mar 2026 Revenue of ₹771.66 Cr (+16.7% YoY); net profit ₹41.05 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +3.9%, earnings +37.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%, profit CAGR 4.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.52%
1 Year:3.90%

Compounded Profit Growth

5 Years:4.30%
1 Year:37.30%

Stock Price Performance

1 Year:-6.08%
6 Months:+0.33%
3 Months:+2.44%
1 Month:-14.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 46% of range
₹65.75 ₹96.74
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)39.33 · Neutral
Price Performance
1M-14.72%
3M+2.44%
6M+0.33%
1Y-6.08%
Valuation vs Sector

P/E of 18.15 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.15
Industry PE
36.43
Forward P/E est.
13.22
PEG Ratio
-
Book Value
₹35.14
Price to Book
2.33
P/S
1.06
EV/EBITDA
10.36
Dividend Yield
1.83%

Growth (CAGR)

Revenue 5Y
13.52%
Profit 5Y
4.30%
Revenue (YoY)
3.90%
Earnings (YoY)
37.30%

Profitability & Returns

ROCE
15.43%
ROE
11.65%
ROA
7.36%
Profit Margin
5.67%
Op Margin
7.15%
Gross Margin
22.43%
EPS (Latest Qtr)
₹1.17
EPS (TTM)
₹4.40

Balance Sheet & Liquidity

Debt/Equity
0.02
Quick Ratio
1.50
Current Ratio
2.22
Debt
₹5.83 L
Total Assets
₹557.37 Cr
Current Assets
₹451.32 Cr
Working Capital
₹248.31 Cr

Ownership

Promoter Holding
72.89%
Chg in Prom Hold
0.00%
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹800.49 Cr
Total Revenue (TTM)
₹778.99 Cr
EBITDA
₹74.06 Cr
Free Cash Flow
₹-10.88 Cr
Operating Cash Flow
₹-3.01 Cr
Shares Outstanding
₹10.02 Cr
Gross Margin
22.43%
Payout Ratio
34.01%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ANUHPHR Anuh Pharma Limited NSEPHARMA 79.87 18.15 ₹800.49 Cr 1.83% 15.43% 11.65% 13.52% 4.30%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 198.14 Cr186.48 Cr185.88 Cr197.18 Cr202.12 Cr
Cost of Revenue 148.46 Cr152.62 Cr144.53 Cr151.28 Cr151.23 Cr
Gross Profit 49.68 Cr33.86 Cr41.35 Cr45.90 Cr50.89 Cr
Operating Expenses 33.77 Cr26.08 Cr32.33 Cr32.10 Cr34.01 Cr
Operating Income 15.91 Cr7.78 Cr9.02 Cr13.80 Cr16.88 Cr
EBITDA 20.07 Cr13.68 Cr12.86 Cr20.91 Cr18.63 Cr
Interest Expense 3.35 L21.13 L7.56 L7.96 L10.58 L
Pretax Income 17.28 Cr10.95 Cr9.92 Cr17.83 Cr15.52 Cr
Tax Provision 4.82 Cr2.65 Cr2.31 Cr4.38 Cr3.84 Cr
Net Income 12.46 Cr8.30 Cr7.61 Cr13.45 Cr11.68 Cr
Diluted EPS 1.240.830.761.341.17

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -527.49 Cr647.00 Cr661.51 Cr771.66 Cr
Cost of Revenue -401.48 Cr486.66 Cr499.37 Cr599.66 Cr
Gross Profit -126.00 Cr160.34 Cr162.15 Cr172.00 Cr
Operating Expenses -81.56 Cr92.68 Cr105.31 Cr115.05 Cr
Operating Income -44.45 Cr67.67 Cr56.84 Cr56.94 Cr
EBITDA -57.39 Cr87.25 Cr70.36 Cr66.08 Cr
Interest Expense -21.84 L35.36 L61.93 L47.23 L
Pretax Income -47.47 Cr78.31 Cr61.01 Cr54.22 Cr
Tax Provision -11.29 Cr18.25 Cr13.65 Cr13.18 Cr
Net Income -36.18 Cr60.06 Cr47.35 Cr41.05 Cr
Diluted EPS -3.615.992.364.10

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -404.98 Cr445.68 Cr506.63 Cr557.37 Cr
Current Assets -307.61 Cr338.54 Cr376.17 Cr451.32 Cr
Cash & Equivalents -1.93 Cr7.20 Cr19.56 Cr8.06 Cr
Inventory -72.64 Cr75.40 Cr74.48 Cr147.75 Cr
Receivables -171.23 Cr189.95 Cr215.87 Cr238.63 Cr
Total Liabilities -163.76 Cr154.46 Cr180.60 Cr205.15 Cr
Current Liabilities -161.34 Cr152.69 Cr178.51 Cr203.00 Cr
Long Term Debt -----
Total Debt -90.67 L2.69 Cr10.89 Cr5.83 L
Total Equity -241.22 Cr291.22 Cr326.02 Cr352.22 Cr
Shares Outstanding -10.02 Cr10.02 Cr10.02 Cr10.02 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -53.90 Cr12.93 Cr37.12 Cr-3.01 Cr
Investing Cash Flow --43.48 Cr91.82 L-19.91 Cr17.84 Cr
Financing Cash Flow --12.29 Cr-8.57 Cr-4.86 Cr-26.33 Cr
Capital Expenditure --1.55 Cr-5.02 Cr-20.15 Cr-7.87 Cr
Free Cash Flow -52.35 Cr7.91 Cr16.98 Cr-10.88 Cr
Net Change in Cash --1.87 Cr5.27 Cr12.36 Cr-11.50 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -23.9%24.8%24.5%22.3%
Operating Margin % -8.4%10.5%8.6%7.4%
Net Margin % -6.9%9.3%7.2%5.3%
ROE % -15.0%20.6%14.5%11.7%
ROCE % -18.2%23.1%17.3%16.1%

Shareholding Pattern

Insiders
72.89%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANUHPHR

Google News Wed, 21 Oct 2026

Anuh Pharma Limited (ANUHPHR.BO) stock price, news, quote and history - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE1IZGRMajdHWElSOVBMUVBZR0tEQjQ5bjFER201WmgtZ0hlREJtQktNVlpIQ2FMdEt5VklTMjFBSjZ2M19uNG91ZnBYSG1fZmJLWEZtUXFYQ3k5ZkZuTTVSQmlxQXRSeU5j?oc=5" target="_blank">Anuh Pharma Limited (ANUHPH…

Google News Wed, 20 May 2026

ANUHPHR: Revenue up 17% to ₹77,166 lakhs; net profit down 13%; 1:1 bonus issue and ₹1.50 dividend - TradingView

<a href="https://news.google.com/rss/articles/CBMigwJBVV95cUxPaE1uODFoc19mc2dIa0gwS0Y0MnBVWUlXZ2xjUDQtQldlbWUyQVFOMHdYdXJGUml4OXAtV1pMdDJ0OVVwenAzNDZXYWtVUzVlYkY0M21OT1BMeF9IcVExRURKR3ZiTmlRbzFuV3gxWVZDdHpKdXJmVHM4akVienljS2hjT3I1YWdwb0ZGdH…

Google News Wed, 21 Oct 2026

Anuh Pharma ANUHPHR Takes Possession of Tarapur Facility - Kalkine India

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQb2RHRlJNT0JoRFpaRjBiYWRwSkJxdWt2aTl0LURyYnhtdlpUTEtkWVBaNGRoUEpJVWFuR2tuNF9WRmgwdWoxd2FsZWVCekY5S3lLcFRkYTNaU3pLdkM3c2xDNFdXN0p3RWJUVnVYM2xkYUl4SmRqa2JBLUhRdms2dC1HOVlWTzhpalhnSl…

Google News Sun, 27 Sep 2026

Anuh Pharma (ANUHPHR.NS) Edges Up to ₹91.12, Holding Above ₹86.56 Support - Block Trade Flow - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQejNoNksycmlRLWM2YS1CTkltWE13MHd6U3dpWUFiNHBpaEJMNWFQUlJOcjBnV2dPOF9DZUZZYnFKNW9laVdxT0FZcDRsc3hMZExEZzNpTC14QTExdnBWdjYxMnZoTFh5cHotZ0o5NmowSHFETUllb29UN3JrOFVRYUlGY3N3NzM3ZWhUcl…

Google News Wed, 04 Feb 2026

Lacklustre Performance Is Driving Anuh Pharma Limited's (NSE:ANUHPHR) Low P/E - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOb24zN3p1TXUwNm4xVXFmSmNodFJCbGE1a0pHWkZIN1pYelRSVnpjbWN2QUU5SndTZUNnNGtpaUR4c1o4US1Mb1ZGS1pXNWlwVjRfV01RbS1iNHNHMkF5YVFaNXBmUmZGSEJZakRUdVZHX2lROEhwZU5laWNJWDh2bEt6UGMtRWZNSHlneX…

Google News Mon, 28 Sep 2026

Anuh Pharma (ANUHPHR.NS) Slips 1.06% to ₹89.46: Support at ₹84.99, Resistance at ₹93.93 in Focus - Low Vol Factor - siam.in

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNVUlZaGRiSW84UEFQVmpWT2YzbEVqdU5yVW5wRU9wdU5rTmUwTTJhRk91b1k5enJON1pYLWs2V0FfSXF2RHV3TjVqVmhXb1c1THZ4TUNkWXhzVmppcDRYV2U5TDhNQ3FBWmhzSlBvUlFqQlByWkFZMHNFZW9jMTgwZ1JRSUR3dnJDdFNZOU…

ANUHPHR — Frequently Asked Questions

What is the current share price of Anuh Pharma Limited (ANUHPHR)?

As of 2026-10-23 04:58 IST, Anuh Pharma Limited (ANUHPHR) trades at ₹79.87 on NSE. Its 52-week range is ₹65.75 to ₹96.74.

What is the market capitalisation of ANUHPHR?

Anuh Pharma Limited (ANUHPHR) has a market capitalisation of ₹800.49 Cr on NSE.

What is the P/E ratio of ANUHPHR?

ANUHPHR trades at a trailing price-to-earnings (P/E) ratio of 18.15. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.33.

Does ANUHPHR pay a dividend?

Anuh Pharma Limited (ANUHPHR) currently offers a dividend yield of 1.83%.

What is the return on equity (ROE) of ANUHPHR?

ANUHPHR has a return on equity (ROE) of 11.65%. Its return on capital employed (ROCE) is 15.43%.

Is ANUHPHR a good stock to buy?

This page provides a data-driven analysis of Anuh Pharma Limited (ANUHPHR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space